"This FDA approval represents a disruptive paradigm shift in treatment options for millions of people who are frustrated and ...

Lenz Therapeutics has received approval from the Food and Drug Administration for Vizz (aceclidine ophthalmic solution) 1.44% ...

It is anticipated that Vizz, manufactured by Lenz Therapeutics, will become commercially available in the US by the end of ...

Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

The Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

The U.S. Food and Drug Administration has approved Vizz 1.44% (aceclidine ophthalmic solution) for the treatment of ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours ...

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.

The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...